<DOC>
	<DOC>NCT02554292</DOC>
	<brief_summary>The main objective of the SeQuent® Please Neo post market surveillance is to assess the clinical suitability of the combination of pre-dilatation using the NSE Alpha scoring balloon before the use of the paclitaxel-coated SeQuent® Please Neo in an 'all comer'/ 'real world' setting for the treatment of in-stent restenosis.</brief_summary>
	<brief_title>Post Market Surveillance of SeQuent Please Neo With Scoring Balloon</brief_title>
	<detailed_description>The aim of this post market surveillance is to document the safety and efficacy of the drug-coated balloon Sequent® Please Neo in combination with the NSE Alpha scoring balloon in the treatment of in-stent restenosis following coronary stent implantation in native coronary arteries with reference diameters of 2.5 mm up to 4.0 mm with lesion lengths of 30 mm for procedural success and preservation of vessel patency</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>patients with instent restenosis in coronary arteries Intolerance to paclitaxel and/or the balloon coating Allergy to components of the balloon coating Pregnancy and lactation Complete occlusion of the treatment vessel Severely calcified stenosis Cardiogenic shock Risk of an intraluminal thrombus Haemorrhagic diathesis or another disorder such as gastrointestinal ulceration or cerebral circulatory disorders which restrict the use of platelet aggregation inhibitor therapy and anticoagulation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>